Related Experiment Video
Updated: Jul 3, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
Published on: April 21, 2022
Clinical impact of mucus plugs in bronchiectasis
Alessandro De Angelis1,2, Lidia Perea3, Pau Marrades3,4,5
1Respiratory Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milan, 20089, Italy.
None:
Mucus plugging is a common radiological finding in bronchiectasis, but its clinical relevance and its association with patient-reported outcomes remain uncertain. We aimed to determine whether the presence of mucus plugs (MP) is associated with worse respiratory symptoms and whether MP extent correlates with symptom severity. We conducted a cross-sectional study including 133 adults with clinically and radiologically confirmed bronchiectasis attending a specialist outpatient clinic. MP were assessed on chest CT using a segment-based scoring system. Respiratory symptoms were evaluated using the Quality of Life-Bronchiectasis Respiratory Symptoms Score (QoL-B RSS) and the Chronic Airways Assessment Test (CAAT). Associations were explored using non-parametric analyses and multivariable regression models adjusted for sex and Bronchiectasis Severity Index (BSI). MP were identified in 88 patients (66%). Compared with those without MP, patients with MP had significantly worse QoL-B RSS (median 77.8 vs. 83.3; p = 0.01) and higher CAAT scores (10.0 vs. 7.0; p = 0.04). MP extent correlated inversely with QoL-B RSS (ρ=-0.27, p = 0.002) and weakly with CAAT (ρ = 0.19, p = 0.03). Patients with high MP burden (> 5 segments) reported significantly worse QoL-B RSS than those without MP (p = 0.01). MP presence was independently associated with chronic Pseudomonas aeruginosa infection after adjustment for sex and disease severity (adjusted OR 5.6, 95% CI 1.31-39.9; p = 0.03). Mucus plugging is associated with worse respiratory symptoms and chronic Pseudomonas aeruginosa infection and may represent a clinically relevant imaging marker of disease activity in bronchiectasis.
Related Concept Videos
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
